Please login to the form below

Not currently logged in
Email:
Password:

Basilea appoints commercial head

David Veitch spent 15 years at BMS

Switzerland-based biopharma Basilea has appointed David Veitch as chief commercial officer, effective September 1, 2014.

Veitch will lead the company's commercial operations, including sales, marketing and pricing.

He joins from Savient Pharmacueticals where he served as president of the company's' European operations. It's at Bristol-Myers Squibb (BMS) where Veitch has spent most of his career, however, serving at the company from 1996 to 2011 when he joined Savient.

Veitch's most senior role at BMS was senior VP for EMEA marketing and brand commercialisation.

Ronald Scott, CEO of Basilea, commented that Veitch's “extensive experience and in-depth knowledge of European pharmaceutical markets will be instrumental” as the company prepares to launch its antibiotic Zevtera in Europe in 2015.

19th August 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics